Head-To-Head Review: TScan Therapeutics (NASDAQ:TCRX) versus Sera Prognostics (NASDAQ:SERA)

TScan Therapeutics (NASDAQ:TCRX) and Sera Prognostics (NASDAQ:SERA) are both small-cap healthcare companies, but which is the better investment? We will contrast the two companies based on the strength of their institutional ownership, dividends, earnings, risk, analyst recommendations, valuation and profitability.

Analyst Recommendations

This is a summary of recent ratings and recommmendations for TScan Therapeutics and Sera Prognostics, as provided by MarketBeat.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
TScan Therapeutics	1	5	2	0	2.12
Sera Prognostics	1	0	1	1	2.67

TScan Therapeutics currently has a consensus target price of $2.67, suggesting a potential upside of 1,133.43%. Sera Prognostics has a consensus target price of $5.50, suggesting a potential upside of 169.61%. Given TScan Therapeutics’ higher probable upside, equities analysts clearly believe TScan Therapeutics is more favorable than Sera Prognostics.

Profitability

This table compares TScan Therapeutics and Sera Prognostics’ net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
TScan Therapeutics	-1,655.35%	-108.72%	-54.47%
Sera Prognostics	-47,475.72%	-46.71%	-34.06%

Institutional and Insider Ownership

82.8% of TScan Therapeutics shares are owned by institutional investors. Comparatively, 54.6% of Sera Prognostics shares are owned by institutional investors. 6.2% of TScan Therapeutics shares are owned by insiders. Comparatively, 11.3% of Sera Prognostics shares are owned by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock will outperform the market over the long term.

Volatility & Risk

TScan Therapeutics has a beta of 1.15, meaning that its stock price is 15% more volatile than the S&P 500. Comparatively, Sera Prognostics has a beta of 1.06, meaning that its stock price is 6% more volatile than the S&P 500.

Earnings & Valuation

This table compares TScan Therapeutics and Sera Prognostics”s gross revenue, earnings per share (EPS) and valuation.

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
TScan Therapeutics	$10.32 million	1.42	-$129.77 million	($0.91)	-0.24
Sera Prognostics	$80,000.00	1,005.98	-$31.93 million	($0.67)	-3.04

Sera Prognostics has lower revenue, but higher earnings than TScan Therapeutics. Sera Prognostics is trading at a lower price-to-earnings ratio than TScan Therapeutics, indicating that it is currently the more affordable of the two stocks.

Summary

Sera Prognostics beats TScan Therapeutics on 8 of the 15 factors compared between the two stocks.

About TScan Therapeutics

TScan Therapeutics, Inc., a clinical-stage biopharmaceutical company, develops T cell receptor-engineered T cell (TCR-T) therapies for the treatment of patients with cancer in the United States. The company's lead product candidates include TSC-100 and TSC-101 that is in Phase I clinical trial for the treatment of patients with hematologic malignancies to eliminate residual disease and prevent relapse after allogeneic hematopoietic cell transplantation. It also develops TSC-200, TSC-201, TSC-203, and TSC-204, which are in Phase 1 clinical trial, for the treatment of solid tumors; and TSC-202 to treat solid tumors. In addition, the company develops vaccines for infectious diseases, such as SARS-CoV-2. It has collaborations with Novartis Institutes for BioMedical Research, Inc. To discover and develop novel TCR-T therapies; and Amgen Inc. to identify antigens recognized by T cells in patients with Crohn's disease using TargetScan, a proprietary target discovery platform. TScan Therapeutics, Inc. was incorporated in 2018 and is headquartered in Waltham, Massachusetts.

About Sera Prognostics

Sera Prognostics, Inc., a women's health diagnostic company, discovers, develops, and commercializes biomarker tests for improving pregnancy outcomes in the United States. The company develops PreTRM test, a blood-based biomarker test to predict the risk of spontaneous preterm birth in singleton pregnancies. It is also developing a portfolio of product candidates for various pregnancy-related conditions, including preterm birth, preeclampsia, molecular time-to-birth, predictive analytics, gestational diabetes mellitus, fetal growth restriction, stillbirth, and postpartum depression. The company was incorporated in 2008 and is headquartered in Salt Lake City, Utah.